Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 6:13 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 13,066 matching trials from the live ClinicalTrials.gov search.

Filters: Atlanta, Georgia Clear all

Conditions: Tuberculosis
Interventions: Moxifloxacin (with rifampin, pyrazinamide, and ethambutol), isoniazid; Drug
Lead sponsor: Centers for Disease Control and Prevention; Federal
Eligibility: 18 Years and older
Enrollment: 433 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 20
States / cities: Little Rock, Arkansas • Los Angeles, California • San Diego, California + 16 more

Conditions: Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
Interventions: Elecoglipron, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 6,950 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 120
States / cities: Fairhope, Alabama • Anchorage, Alaska • Gilbert, Arizona + 105 more

Conditions: Influenza Virus
Interventions: Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV), Non-adjuvanted Trivalent Influenza Vaccine (TIV) / Quadrivalent Influenza Vaccine (QIV); Biological
Lead sponsor: Seqirus; Industry
Eligibility: 6 Months to 71 Months
Enrollment: 10,644 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 91
States / cities: Chandler, Arizona • Harrisburg, Arkansas • Anaheim, California + 70 more

Conditions: Prostate Cancer
Interventions: flutamide, Zoladex, Lupron, radiation therapy; Drug · Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older · Male only
Enrollment: 2,028 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1994 – 2018
U.S. locations: 222
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 173 more

Conditions: Alzheimer Disease
Interventions: Low Dose Benfotiamine, High Dose Benfotiamine, Placebo; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 50 Years to 89 Years
Enrollment: 406 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 47
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 35 more

Conditions: Genu Recurvatum, Crouch Gait
Interventions: Pediatric Knee Exoskeleton; Device
Lead sponsor: Georgia Institute of Technology; Other
Eligibility: 4 Years to 21 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Chronic Pain
Interventions: Transcranial Direct Current Stimulation; Device
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 89 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Coronary Angiography, Chest Pain
Interventions: Multi-slice Computed Tomography, Rest-stress Nuclear Myocardial Perfusion Imaging; Procedure
Lead sponsor: Corewell Health East; Other
Eligibility: 25 Years and older
Enrollment: 750 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 16
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Weston, Florida + 13 more

Conditions: Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection, COVID-19, Long COVID, Long Haul COVID
Interventions: TNX-102 SL, Placebo SL Tablet; Drug
Lead sponsor: Tonix Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 29
States / cities: Birmingham, Alabama • Oceanside, California • Santa Ana, California + 25 more

Conditions: Psoriatic Arthritis, Obesity
Interventions: Ixekizumab, Tirzepatide; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 279 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 81
States / cities: Avondale, Arizona • Chandler, Arizona • Flagstaff, Arizona + 75 more

Conditions: Crohn's Disease
Interventions: autologous mesenchymal stromal cell; Biological
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2012
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions: carboplatin, oglufanide disodium, paclitaxel, conventional surgery; Drug · Procedure
Lead sponsor: Cytran; Industry
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 19
States / cities: Glendale, California • Los Gatos, California • Stanford, California + 15 more

Conditions: Stage IIIA Non-Small Cell Lung Cancer
Interventions: Neoadjuvant Cisplatin, nab-paclitaxel, Adjuvant Cisplatin,nab-paclitaxel, Adjuvant cisplatin+pemetrexed or cisplatin+gemcitabine; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 9
States / cities: Tampa, Florida • Atlanta, Georgia • Kansas City, Kansas + 6 more

Conditions: Cerebrotendinous Xanthomatosis (CTX)
Interventions: Not listed
Lead sponsor: Travere Therapeutics, Inc.; Industry
Eligibility: 2 Years to 21 Years
Enrollment: 442 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 44
States / cities: Birmingham, Alabama • La Jolla, California • Los Angeles, California + 38 more

Conditions: Soft Tissue Sarcoma
Interventions: Olaratumab, Gemcitabine, Docetaxel, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 16 Years and older
Enrollment: 310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 21
States / cities: Santa Monica, California • Aurora, Colorado • Jacksonville, Florida + 17 more

Conditions: Prostate Cancer (Adenocarcinoma)
Interventions: Abiraterone, Enzalutamide, Apalutamide, Darolutamide (BAY 1841788), Docetaxel, ADT; Drug
Lead sponsor: Canadian Cancer Trials Group; Network
Eligibility: 18 Years and older · Male only
Enrollment: 830 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 374
States / cities: Anchorage, Alaska • Fairbanks, Alaska • Phoenix, Arizona + 272 more

Conditions: Type 2 Diabetes
Interventions: Placebo for Nasulin, Nasulin; Other · Drug
Lead sponsor: CPEX Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 21
States / cities: Chandler, Arizona • Escondido, California • La Jolla, California + 17 more

Conditions: Adenocarcinoma, Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms
Interventions: MiCK Assay; Procedure
Lead sponsor: Pierian Biosciences; Industry
Eligibility: Female only
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Biphenotypic Leukemia, Acute Undifferentiated Leukemia, CLL (Chronic Lymphocytic Leukemia), Chronic Myeloid Leukemia (CML), MDS (Myelodysplastic Syndrome), Non-Hodgkin Lymphomas, Hodgkins Lymphoma, Cutaneous T Cell Lymphomas (CTCL)
Interventions: Ossium HPC Marrow, Bone Marrow Transplant, Pre-transplant conditioning - Myeloablative (MAC), Pre-transplant conditioning - Reduced Intensity (RIC), Post-transplant treatment; Other
Lead sponsor: Ossium Health, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 9
States / cities: Duarte, California • Tampa, Florida • Atlanta, Georgia + 6 more

Conditions: Autoimmune Diseases of the Nervous System, Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Disease Progression, Brain Atrophy
Interventions: Tcelna, Placebo; Biological
Lead sponsor: Opexa Therapeutics, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 33
States / cities: Phoenix, Arizona • Tucson, Arizona • Berkeley, California + 28 more

Conditions: Candidiasis
Interventions: Eraxis (anidulafungin), Diflucan (fluconazole), Vfend (voriconazole); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 282 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 39
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 25 more

Conditions: Adult Rhabdomyosarcoma, Embryonal Childhood Rhabdomyosarcoma, Embryonal-botryoid Childhood Rhabdomyosarcoma, Previously Untreated Childhood Rhabdomyosarcoma
Interventions: conventional surgery, dactinomycin, cyclophosphamide, vincristine sulfate, radiation therapy; Procedure · Drug · Radiation
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 49 Years
Enrollment: 390 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2021
U.S. locations: 138
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 113 more

Conditions: Opioid Use Disorder
Interventions: Not listed
Lead sponsor: Indivior Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 35
States / cities: Costa Mesa, California • Escondido, California • Westport, Connecticut + 31 more

Conditions: Lymphoma
Interventions: rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate, tositumomab and iodine I 131 tositumomab; Biological · Drug · Radiation
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years to 120 Years
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2015
U.S. locations: 78
States / cities: Anchorage, Alaska • Tucson, Arizona • Duarte, California + 46 more

Search by objective public record fields.

TBTC Study 28: Moxifloxacin Versus Isoniazid for TB Treatment

A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF

Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of Investigational Flu Vaccine Compared to Approved Flu Vaccine in Children.

Radiation Therapy With or Without Antiandrogen Therapy in Treating Patients With Stage I or Stage II Prostate Cancer

A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)

Engaging Kids With Robotic Exoskeletons and Gamification

Reboot Pain (tDCS)

Coronary Computed Tomography for Systematic Triage of Acute Chest Pain Patients to Treatment (CT-STAT)

A Phase 2 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Patients With Multi-Site Pain Associated With Post-Acute Sequelae of SARS-CoV-2 Infection

Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight

A Phase I Study Evaluating Autologous Bone Marrow Derived Mesenchymal Stromal for Crohn's Disease.

Combination Chemotherapy Plus IM-862 in Treating Patients With Resected Stage III Ovarian Cancer or Primary Peritoneal Cancer

Cisplatin and Nab-paclitaxel for (N2) Defined NSCLC

Cerebrotendinous Xanthomatosis (CTX) Prevalence Study

A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

Effects of Nasulin Versus Placebo on Blood Glucose Control in Patient Volunteers With Type 2 Diabetes Mellitus

Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas

A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies

Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis

Study Will Evaluate The Safety And Efficacy Of Anidulafungin In Patients With Candidemia Or Invasive Candidiasis

Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma

SUBLOCADE Long-term Outcomes

S0433 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Treating Older Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma